Australia markets closed

Orexo AB (publ) (ORXOF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.58000.0000 (0.00%)
At close: 09:35AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.5800
BidN/A x N/A
AskN/A x N/A
Day's range2.5800 - 2.5800
52-week range2.3500 - 4.0244
Avg. volume15
Market cap60.858M
Beta (5Y monthly)0.83
PE ratio (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Orexo's partner Trinity Health today announces the availability of vorvida® and deprexis® to patients

    Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo's evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking.

  • PR Newswire

    First patent issued in Europe for Orexo's adrenaline product OX640

    Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the European Patent Office (EPO) has granted the first European patent specifically relating to OX640, Orexo's nasal adrenaline rescue medication based on the amorphOX® drug delivery platform.

  • PR Newswire

    Orexo to participate in Pareto Securities´ 13th Annual Healthcare Conference

    Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), which develops improved pharmaceuticals and evidence-based digital therapeutics primarily targeting the US market where its commercial organization is located, today announces the company will participate in Pareto Securities' 13th Annual Healthcare Conference, that takes place on September 7-8, 2022, at Sergel Hub, Sveavägen 10 A, Stockholm, Sweden.